Skip to main content

Table 1 Baseline characteristics of the study population

From: Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study

Variable Nevirapine
n = 144
Efavirenz
n = 140
P value
Age, years: Mean ± SD 36.7 ± 8.7 36.7 ± 7.6  
Gender, number (%)
 Male 104 (72.2%) 111 (79.3%)  
 Female 40 (28.8%) 29 (20.7%)
BMI, Kg/m2 Mean ± SD 18.1 ± 3.3 18.5 ± 3.3  
CD4 count, cells/ul Median (Range) 127 (9–569) 133 (7–588) 0.47
Viral load/ml Median (Range) 334,225 (120–5,000,000) 173,000 (230–5,800,000) 0.17
WHO staging of HIV disease, number (%) 
 Stage-1 4 (2.9%) 3 (2.2%) 0.03
 Stage-3 39 (27.8%) 21 (15.3%) 0.04
 Stage-4 97 (69.3%) 113 (82.5%) 0.04
Type of tuberculosis, number (%)
 PTB 17 (16%) 24 (20.7%) 0.07
 EPTB 69 (65%) 82 (70.7%)  
 Disseminated/Miliary TB 20 (19%) 10 (8.6%)  
Category of ATT, number (%)    0.52
 Category I 124 (86.8%) 124 (89.2%)  
 Category II 19 (13.3%) 15 (10.8%)
ATT-ART gap, days: Median (Range) 27 (−1 to 100) 26 (4 to 96) 0.33